MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors

BACKGROUND: Contemporary challenges of prostate cancer (PCa) include overdiagnosis and overtreatment, entailing the need for novel clinical tools to improve risk stratification and therapy selection. PCa diagnosis and prognostication might be perfected using epigenetic biomarkers, among which aberra...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres-Ferreira, Jorge, Ramalho-Carvalho, João, Gomez, Antonio, Menezes, Francisco Duarte, Freitas, Rui, Oliveira, Jorge, Antunes, Luís, Bento, Maria José, Esteller, Manel, Henrique, Rui, Jerónimo, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282784/
https://www.ncbi.nlm.nih.gov/pubmed/28143614
http://dx.doi.org/10.1186/s12943-017-0604-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282784/
https://www.ncbi.nlm.nih.gov/pubmed/28143614
http://dx.doi.org/10.1186/s12943-017-0604-0

Ejemplares similares